Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C15H21NO4.ClH |
| Molecular Weight | 315.792 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CCN(CC)CCOC(=O)C1=C(OC(C)=O)C=CC=C1
InChI
InChIKey=BILQGNUILZKMKV-UHFFFAOYSA-N
InChI=1S/C15H21NO4.ClH/c1-4-16(5-2)10-11-19-15(18)13-8-6-7-9-14(13)20-12(3)17;/h6-9H,4-5,10-11H2,1-3H3;1H
| Molecular Formula | C15H21NO4 |
| Molecular Weight | 279.3315 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Aspirin is a nonsteroidal anti-inflammatory drug. Aspirin is unique in this class of drugs because it irreversibly inhibits both COX-1 and COX-2 activity by acetylating a serine residue (Ser529 and Ser516, respectively) positioned in the arachidonic acid-binding channel, thus inhibiting the synthesis of prostaglandins and reducing the inflammatory response. The drug is used either alone or in combination with other compounds for the treatment of pain, headache, as well as for reducing the risk of stroke and heart attacks in patients with brain ischemia and cardiovascular diseases.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: P23219|||Q5T7T7 Gene ID: 5742.0 Gene Symbol: PTGS1 Target Organism: Homo sapiens (Human) |
1.2 µM [IC50] | ||
Target ID: P35354 Gene ID: 5743.0 Gene Symbol: PTGS2 Target Organism: Homo sapiens (Human) |
5.2 µM [IC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | SYNALGOS-DC Approved UseSYNALGOS-DC is a combination of dihydrocodeine, an opioid agonist, aspirin, a nonsteroidal anti-inflammatory drug, and caffeine, a methylxanthine, and is indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Launch Date1958 |
|||
| Primary | FIORINAL Approved UseFIORINAL is indicated for the relief of the symptom complex of tension (or muscle contraction) headache. Evidence supporting the efficacy and safety of Fiorinal in the treatment of multiple recurrent headaches is unavailable. Caution in this regard is required because butalbital is habit-forming and potentially abusable. Launch Date1976 |
|||
| Preventing | DURLAZA Approved UseDURLAZA is a nonsteroidal anti-inflammatory drug indicated to reduce the risk of death and myocardial infarction (MI) in patients with chronic coronary artery disease, such as patients with a history of MI or unstable angina pectoris or with chronic stable angina and to reduce the risk of death and recurrent stroke in patients who have had an ischemic stroke or transient ischemic attack. Launch Date2015 |
|||
| Preventing | AGGRENOX Approved UseAGGRENOX is indicated to reduce the risk of stroke in patients who have had transient ischemia of the brain or completed ischemic stroke due to thrombosis. Launch Date1999 |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
54.25 mg/L EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/24672263 |
500 mg single, intravenous dose: 500 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
ASPIRIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
4.84 mg/L EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/24672263 |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
ASPIRIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
10.31 mg × h/L EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/24672263 |
500 mg single, intravenous dose: 500 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
ASPIRIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
5.12 mg × h/L EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/24672263 |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
ASPIRIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
0.322 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/24672263 |
500 mg single, intravenous dose: 500 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
ASPIRIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
0.422 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/24672263 |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
ASPIRIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Funbound
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
68% |
ASPIRIN plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Overview
| CYP3A4 | CYP2C9 | CYP2D6 | hERG |
|---|---|---|---|
OverviewOther
Drug as perpetrator
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
| no | ||||
| no | ||||
| no | ||||
Page: - |
yes | |||
| yes | ||||
| yes | ||||
| yes | ||||
Page: - |
yes |
Drug as victim
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| yes [Km 1242 uM] | ||||
| yes [Km 2337 uM] | ||||
| yes [Km 278.6 uM] | ||||
| yes [Km 40.7 uM] | ||||
| yes [Km 683.1 uM] | ||||
| yes [Km 698.2 uM] | ||||
| yes [Km 94.2 uM] | ||||
| yes | ||||
| yes | ||||
| yes | ||||
| yes | ||||
| yes | ||||
| yes | ||||
| yes | ||||
| yes |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Letter: Aspirin sensitivity: other drugs. | 1975 Feb |
|
| Studies on the modification of renal lesions due to aspirin and oxyphenbutazone in the rat and the effects on the kidney of 2:4 dinitrophenol. | 1976 Jul |
|
| Severe gastrointestinal hemorrhage and anemia after therapeutic doses of aspirin in normal children. | 1976 Mar |
|
| Analgesic-induced renal papillary necrosis in the Gunn rat: the comparative nephrotoxicity of aspirin and phenacetin. | 1976 Nov |
|
| Statins and peripheral neuropathy. | 1999 Jan |
|
| Leptin in gastroprotection induced by cholecystokinin or by a meal. Role of vagal and sensory nerves and nitric oxide. | 1999 Jun 18 |
|
| Enhancement of low density lipoprotein catabolism by non-steroidal anti-inflammatory drugs in cultured HepG2 cells. | 1999 May 21 |
|
| Iron deficiency anaemia and aspirin use in old age. | 1999 Sep |
|
| Sleep attacks (sleep episodes) with pergolide. | 2000 Apr 15 |
|
| Transcriptional regulation of cyclooxygenase-2 gene expression: novel effects of nonsteroidal anti-inflammatory drugs. | 2000 Feb 15 |
|
| Intermediate but not low doses of aspirin can suppress angiotensin-converting enzyme inhibitor-induced cough. | 2000 Jul |
|
| Indications for early aspirin use in acute ischemic stroke : A combined analysis of 40 000 randomized patients from the chinese acute stroke trial and the international stroke trial. On behalf of the CAST and IST collaborative groups. | 2000 Jun |
|
| Clinical, biochemical, and genetic characterization of a novel estrogen-dependent inherited form of angioedema. | 2000 Sep |
|
| Novel platelet inhibitors. | 2001 |
|
| Human herpesvirus 8 K1-associated nuclear factor-kappa B-dependent promoter activity: role in Kaposi's sarcoma inflammation? | 2001 |
|
| Cardiac risk factors, medication, and recurrent clinical events after acute coronary disease; a prospective cohort study. | 2001 Feb |
|
| Non-steroidal anti-inflammatory drugs and gastrointestinal damage-problems and solutions. | 2001 Feb |
|
| A novel synthetic inhibitor of factor Xa decreases early reocclusion and improves 24-h patency after coronary fibrinolysis in dogs. | 2001 Feb |
|
| The effects of diaspirin cross-linked hemoglobin on the tone of human saphenous vein. | 2001 Feb |
|
| Renal function and intensive lowering of blood pressure in hypertensive participants of the hypertension optimal treatment (HOT) study. | 2001 Feb |
|
| Use of aspirin, epistaxis, and untreated hypertension as risk factors for primary intracerebral hemorrhage in middle-aged and elderly people. | 2001 Feb |
|
| Antiplatelet drugs for prevention of pre-eclampsia and its consequences: systematic review. | 2001 Feb 10 |
|
| Systematic review of long term anticoagulation or antiplatelet treatment in patients with non-rheumatic atrial fibrillation. | 2001 Feb 10 |
|
| Heterogenous nature of flow-mediated dilatation in human conduit arteries in vivo: relevance to endothelial dysfunction in hypercholesterolemia. | 2001 Feb 2 |
|
| Addition of hydrophilic and lipophilic compounds of biological relevance to the monoolein/water system. I. Phase behavior. | 2001 Jan |
|
| Present treatment options for unstable angina and non-Q-wave myocardial infarction. | 2001 Jan |
|
| Antithrombotic agents in coronary artery disease. | 2001 Jan |
|
| Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves. | 2001 Jan |
|
| Antithrombotic therapy in atrial fibrillation. | 2001 Jan |
|
| Use of antithrombotic agents during pregnancy. | 2001 Jan |
|
| Platelet-active drugs : the relationships among dose, effectiveness, and side effects. | 2001 Jan |
|
| [Leukocytoclastic vasculitis associated with ticlopidine]. | 2001 Jan |
|
| Is optimal antithrombotic therapy after myocardial infarction well defined? | 2001 Jan |
|
| Hemoglobin and methemoglobin concentrations after large-dose infusions of diaspirin cross-linked hemoglobin. | 2001 Jan |
|
| Salicylate and cocaine: interactive toxicity during chicken mid-embryogenesis. | 2001 Jan 15 |
|
| Blood donations and risk of coronary heart disease in men. | 2001 Jan 2 |
|
| Local delivery of enoxaparin to decrease restenosis after stenting: results of initial multicenter trial: Polish-American Local Lovenox NIR Assessment study (The POLONIA study). | 2001 Jan 2 |
|
| Authors' reply on aspirin for primary prevention. | 2001 Jan 20 |
|
| Superiority of clopidogrel versus aspirin in patients with prior cardiac surgery. | 2001 Jan 23 |
Sample Use Guides
Severe pain: Initiate treatment with two capsules (1 capsule contains 16 mg dihydrocodeine bitartrate, 356.4 mg aspirin, and 30 mg caffeine) orally every 4 hours as needed for pain. Headache: One or 2 capsules (1 capsule contains 50 mg butalbital, 325 mg aspirin and 40 mg caffeine) every 4 hours. Total daily dose should not exceed 6 capsules. Prevention of stoke and heart attacks: the recommended dose is one capsule of aspirin (162.5 mg) once daily. Take the capsules with a full glass of water at the same time each day. Prevention of stroke (in combination with dipyridamole): the recommended dose is one capsule (200 mg dipyridamole and 25 mg aspirin) given orally twice daily.
Route of Administration:
Enteral
Human platelet-rich plasma was incubated with various aspirin concentrations (10, 20, 50, 100, 200, 300, 400, 500 uM) at 37C for up to 4.5 h. Platelet aggregation and thromboxane generation were measured. Inhibition of platelet aggregation and thromboxane formation by 10 uM aspirin was maximal by 90 min. There was progressive inhibition by 3 uM aspirin during incubation for 270 min. By the end of this time there was also significant inhibition by 1 uM aspirin.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 08:13:26 GMT 2023
by
admin
on
Sat Dec 16 08:13:26 GMT 2023
|
| Record UNII |
J0TQX5LV1L
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
10245200
Created by
admin on Sat Dec 16 08:13:26 GMT 2023 , Edited by admin on Sat Dec 16 08:13:26 GMT 2023
|
PRIMARY | |||
|
3861-78-7
Created by
admin on Sat Dec 16 08:13:26 GMT 2023 , Edited by admin on Sat Dec 16 08:13:26 GMT 2023
|
PRIMARY | |||
|
LM-74
Created by
admin on Sat Dec 16 08:13:26 GMT 2023 , Edited by admin on Sat Dec 16 08:13:26 GMT 2023
|
PRIMARY | |||
|
J0TQX5LV1L
Created by
admin on Sat Dec 16 08:13:26 GMT 2023 , Edited by admin on Sat Dec 16 08:13:26 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|
